{"id":3187,"date":"2006-06-10T22:46:43","date_gmt":"2006-06-10T21:46:43","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=3187"},"modified":"2013-12-06T18:09:02","modified_gmt":"2013-12-06T18:09:02","slug":"brecanavir-interaction-study-with-ritonavir-and-atazanavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/3187","title":{"rendered":"Brecanavir interaction study with ritonavir and atazanavir"},"content":{"rendered":"<p><strong>Ben Cheng, HIV i-Base<\/strong><\/p>\n<p><strong>Brecanavir is a new protease inhibitor that is currently in clinical studies and it is being studied in combination with low dose ritonavir. A drug interaction study involving 48 HIV-negative individuals participated in this study to evaluate the effects of atazanavir and ritonavir on brecanavir drug levels.<\/strong><\/p>\n<p>The results from the study showed that the addition of atazanavir (300mg once a day) to brecanavir\/ritonavir (300mg\/100mg every 12 hours) led to higher brecanavir, ritonavir and atazanavir drug levels. AUC levels of all drugs increased: brecanavir by an average of 38%, ritonavir by 56% and atazanavir levels by 44%. Results from this study suggest that atazanavir further increases brecanavir levels on top of the increase already seen with low dose ritonavir and a reduction in the dose of atazanavir should be considered.<\/p>\n<p class=\"ref\">Reference:<\/p>\n<p class=\"ref\">Ford S, Murray S, Anderson M et al. Brecanavir\/ritonavir and atazanavir\/ritonavir increased following repeat co-administration. 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006, Lisbon. Abstract 76.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ben Cheng, HIV i-Base Brecanavir is a new protease inhibitor that is currently in clinical studies and it is being studied in combination with low dose ritonavir. A drug interaction study involving 48 HIV-negative individuals participated in this study to &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,34],"tags":[143],"class_list":["post-3187","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pk-and-drug-interactions","tag-pk-workshop-2006"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=3187"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3187\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=3187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=3187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=3187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}